Ernexa Therapeutics Inc.

ERNA

Ernexa Therapeutics Inc.

ERNA

Insider Sentiment (TTM):

Last Purchase:2026-02-10Last Sale:-Shares Purchased (TTM):4,000,000Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:3,574,358Shares Outstanding:792,000Institutional Ownership Pct.:N/A

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash	5	9	2	3	4	2	2	4	3	5	8	5
Other Receivables Net Current	-	-	0	0	0	0	0	0	0	0	0	2
Prepaid Expense And Other Assets Current	1	1	0	0	0	0	0	0	1	1	2	1
Assets Current	6	10	3	3	5	2	2	5	4	6	10	7
Restricted Cash Noncurrent	-	-	-	-	-	-	-	-	4	4	4	4
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	1	1	0	0
Operating Lease Right Of Use Asset	0	0	0	1	1	1	1	1	36	37	33	35
Goodwill	-	-	2	2	2	2	2	2	2	2	2	2
Equity Method Investments	-	-	-	-	-	-	-	-	-	-	0	0
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	4
Assets	6	11	6	6	8	5	5	8	46	50	49	52
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	1	1	1	1	1	2	2	2	2	1	1
Accrued Liabilities Current	1	1	1	1	1	1	1	1	2	2	2	5
Taxes Payable Current	-	0	0	0	0	0	0	0	0	0	0	0
Bridge Loan	-	-	-	-	-	-	-	1	-	-	-	-
Derivative Liabilities Current	-	-	-	-	-	-	-	5	-	-	-	-
Operating Lease Liability Current	0	0	0	0	0	0	0	0	4	3	2	1
Deferred Revenue Current	-	-	-	-	-	-	-	-	0	0	0	0
Contract With Customer Liability Current	-	-	-	-	-	5	-	-	-	-	-	-
Notes Payable Current	-	-	-	-	-	2	-	-	-	-	-	-
Business Combination Contingent Consideration Liab…	-	0	0	0	0	-	-	-	-	-	-	-
Other Liabilities Current	0	0	0	0	0	-	-	0	0	1	-	-
Liabilities Current	3	3	3	2	3	10	3	10	10	8	7	10
Convertible Long Term Notes Payable	-	-	-	-	-	-	-	32	9	8	7	3
Derivative Liabilities Noncurrent	-	-	-	-	-	-	0	10	0	0	0	0
Operating Lease Liability Noncurrent	0	0	0	0	0	0	0	1	36	37	33	35
Deferred Revenue Noncurrent	-	-	-	-	-	-	-	-	0	0	0	0
Business Combination Contingent Consideration Liab…	-	-	-	-	-	0	0	0	0	0	0	0
Other Liabilities Noncurrent	0	0	0	0	0	0	0	0	0	0	0	-
Liabilities	3	4	3	3	3	11	4	53	55	53	47	49
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	-	0	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	258	258	248	248	247	234	233	1	191	190	189	184
Retained Earnings Accumulated Deficit	-255	-251	-246	-244	-243	-240	-232	-226	-199	-194	-187	-181
Stockholders Equity	3	7	2	4	4	-6	2	-45	-9	-3	2	4
Liabilities And Stockholders Equity	6	11	6	6	8	5	5	8	46	50	49	52
Preferred Stock Par Or Stated Value Per Share	0.005	0.005	0.005	0.005	0.005	0.005	0.005	0.005	0.005	0.005	0.005	0.005
Preferred Stock Shares Authorized	1	1	1	1	1	1	1	1	1	1	1	1
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Liquidation Preference Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.005	0.005	0.005	0.005	0.005	0.005	0.005	0.005	0.005	0.005	0.005	0.005
Common Stock Shares Authorized	150	150	150	150	150	100	100	100	100	100	100	100
Common Stock Shares Issued	1	1	0	0	0	0	0	0	0	0	0	0
Shares Outstanding	1	1	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	9.43%	-13.04%	-54.51%	-	-	-	-	-	-	-	-	-
2025	4.76%	-41.27%	-38.10%	-23.31%	-26.38%	15.34%	-22.86%	-30.86%	-31.43%	-37.50%	-53.12%	32.12%
2024	-17.87%	-20.43%	-24.26%	-16.11%	-40.56%	-42.22%	-62.96%	-68.52%	-64.81%	-26.92%	-23.08%	-15.38%
2023	-	-	-	-14.93%	-18.66%	-48.88%	35.65%	66.96%	42.61%	0.46%	-15.07%	-13.24%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	2.01	2.89	1.01	1.58	1.81	0.21	0.80	0.48	0.37	0.79	1.46	0.73
Quick Ratio	1.74	2.68	0.88	1.49	1.69	0.20	0.74	0.45	0.29	0.70	1.22	0.66
Working Capital	2.96M	6.54M	20.00K	1.24M	2.14M	-8.23M	-586.00K	-5.22M	-6.02M	-1.60M	3.03M	-2.60M
Leverage & Debt
Debt to Equity	0.97	0.54	1.43	0.73	0.71	-1.85	2.10	-1.17	-6.45	-15.55	21.00	13.67
Interest Coverage TTM	-101.34	-133.84	-175.83	-31.60	-33.73	-41.10	-22.14	-37.19	-36.77	-35.59	-105.15	-145.70
Debt Ratio	0.49	0.35	0.59	0.42	0.41	2.18	0.68	6.88	1.18	1.07	0.95	0.93
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.02	0.02	0.02	0.02	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-10.37	-14.40	-55.89	-55.74	-211.13	-324.61	-1,223.60	-3,112.26	-1,657.06	-1,586.48	-1,528.30	-1,386.53
Free Cash Flow Per Share TTM	-7.50	-9.16	-27.96	-28.68	-69.79	-101.56	-445.19	-1,200.83	-1,167.73	-1,262.72	-1,440.77	-1,468.97
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.06	0.22	1.11	1.11	1.11	1.13	1.11
Margin Metrics
Gross Profit Margin TTM	-	-	-	-	-	-	83.51%	72.91%	-111.11%	-	-	-
Operating Profit Margin TTM	-	-	-	-992,100.00%	-2,087.50%	-2,358.32%	-2,693.13%	-3,134.11%	-13,572.84%	-18,787.83%	-31,080.88%	-39,425.49%
Net Profit Margin TTM	-	-	-	-1,834,000.00%	-8,955.74%	-8,615.70%	-7,652.75%	-7,515.22%	-14,770.37%	-19,912.17%	-31,864.71%	-39,241.18%
Growth Metrics
Net Revenue Growth (1Y)	-100.00%	-100.00%	-100.00%	-99.83%	201.23%	365.22%	755.88%	1,072.55%	-	-	-	-
Net Income Growth (1Y)	-71.93%	-75.26%	-68.34%	-59.19%	82.65%	101.29%	105.55%	124.56%	10.07%	10.97%	-11.90%	-28.67%
EPS Growth (1Y)	-95.09%	-95.56%	-95.43%	-98.21%	-87.26%	-79.54%	-19.94%	124.46%	7.85%	5.16%	-49.42%	-61.22%
Valuation Metrics
P/E TTM	-0.64	-0.35	-0.54	-0.49	-0.22	-0.21	-0.09	-0.13	-0.41	-0.57	-0.44	-0.59
P/B TTM	2.46	0.58	3.15	2.53	2.14	-1.61	2.33	-0.13	-1.16	-3.81	4.29	3.31
P/S TTM	-	-	-	9,048.60	19.51	17.92	6.80	9.51	61.17	112.96	140.74	231.37
Market Cap	7.87M	3.96M	7.57M	9.05M	9.52M	9.59M	3.96M	5.69M	9.91M	12.99M	9.57M	11.80M
Enterprise Value	2.84M	-5.22M	5.68M	6.00M	5.21M	9.92M	2.23M	33.46M	16.22M	11.79M	4.67M	6.61M
Calculated Values
Free Cash Flow TTM	-8.88M	-7.26M	-7.05M	-9.44M	-14.45M	-14.42M	-16.21M	-17.34M	-16.86M	-18.23M	-20.43M	-21.20M
Net Debt	-5.03M	-9.18M	-1.88M	-3.05M	-4.32M	332.00K	-1.73M	27.77M	6.31M	-1.20M	-4.90M	-5.19M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-10Purchase

Owner: Cherington, Charles

Title: -

Shares: 4,000,000

Price/Share: $0.50

Value: $2,000,000.00

Shares Owned: 6,779,440

Relationship: TenPercentOwner

Ownership: Direct

2025-06-09Purchase

Owner: Cherington, Charles

Title: -

Shares: 21,241,163

Price/Share: $0.10

Value: $2,124,116.30

Shares Owned: 41,659,743

Relationship: TenPercentOwner

Ownership: Direct

2025-04-02Purchase

Owner: Cherington, Charles

Title: -

Shares: 3,768,397

Price/Share: $0.10

Value: $376,839.70

Shares Owned: 20,401,602

Relationship: TenPercentOwner

Ownership: Direct

2024-10-29Purchase

Owner: Cherington, Charles

Title: -

Shares: 13,252,112

Price/Share: -

Value: -

Shares Owned: 13,808,577

Relationship: TenPercentOwner

Ownership: Direct

2024-09-24Purchase

Owner: Cherington, Charles

Title: -

Shares: 13,252,112

Price/Share: -

Value: -

Shares Owned: 13,808,577

Relationship: TenPercentOwner

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-10	Cherington, Charles	TenPercentOwner	-	Direct	Purchase	4,000,000	0.50	$2,000,000.00	6,779,440	4
2025-06-09	Cherington, Charles	TenPercentOwner	-	Direct	Purchase	21,241,163	0.10	$2,124,116.30	41,659,743	4
2025-04-02	Cherington, Charles	TenPercentOwner	-	Direct	Purchase	3,768,397	0.10	$376,839.70	20,401,602	4
2024-10-29	Cherington, Charles	TenPercentOwner	-	Direct	Purchase	13,252,112	-	-	13,808,577	4
2024-09-24	Cherington, Charles	TenPercentOwner	-	Direct	Purchase	13,252,112	-	-	13,808,577	4/A
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

Inst. Shares: 3,574,358

Shares Outstanding: 792,000

2025-12-31

8.09%

Inst. Shares: 510,085

Shares Outstanding: 6,307,000

2025-09-30

6.28%

Inst. Shares: 516,928

Shares Outstanding: 8,226,000

2025-06-30

0.96%

Inst. Shares: 49,811

Shares Outstanding: 5,179,000

2025-03-31

Inst. Shares: 1,445,925

Shares Outstanding: 142,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	3,574,358	792,000	-
2025-12-31	510,085	6,307,000	8.09%
2025-09-30	516,928	8,226,000	6.28%
2025-06-30	49,811	5,179,000	0.96%
2025-03-31	1,445,925	142,000	-
2024-12-31	994,393	910,000	109.27%
2024-09-30	711,299	361,000	197.04%
2024-06-30	390,077	361,000	108.05%
2024-03-31	399,123	360,847	110.61%
2023-12-31	875,985	354,444	247.14%
2023-09-30	331,434	360,847	91.85%
2023-06-30	333,250	353,710	94.22%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Ernexa Therapeutics Inc. (ERNA) — SEC Financial Statements & Analysis

Ernexa Therapeutics Inc. (ERNA) is a pharmaceutical preparations company, incorporated in DE. Ernexa Therapeutics Inc. trades on Nasdaq as: ERNA, ERNAW. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Ernexa Therapeutics Inc. reported a -100.00% year-over-year revenue growth, a Gross Profit Margin of 83.51% (TTM), a Debt-to-Equity ratio of 0.97x, a Price-to-Sales (P/S) ratio of 9048.60x (TTM), a Price-to-Book (P/B) ratio of 2.46x (TTM), at a market cap of $7.87M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Gross Profit Margin TTM: 83.51%
Debt To Equity: 0.97x
P/S TTM: 9048.60x
P/B TTM: 2.46x
Market Cap: $7.87M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Ernexa Therapeutics Inc. in?

Ernexa Therapeutics Inc. (ERNA) operates in the Pharmaceutical Preparations industry.

What is ERNA's market cap?

Ernexa Therapeutics Inc. (ERNA) has a market capitalization of $7.87M as of 2026-06-30.

What exchange does ERNA trade on?

Ernexa Therapeutics Inc. (ERNA) trades on the Nasdaq.

Where is Ernexa Therapeutics Inc. incorporated?

Ernexa Therapeutics Inc. is incorporated in DE.